FDA approves Isembyld as first muscle-targeted treatment for spinal muscular atrophy
The FDA has approved Isembyld as the first spinal muscular atrophy treatment designed to directly target muscle loss, for patients aged 2 years and older receiving an SMN2-targeted therapy.
Isembyld, also known as apitegromab-mstn, is a muscle-targeted monoclonal antibody that inhibits myostatin activation and is used alongside existing SMN2-targeted treatment for spinal muscular atrophy.
The approval introduces a complementary treatment approach that acts directly on skeletal muscle rather than the underlying SMN pathway, providing a new option for eligible children and adults with SMA.
Field | Content |
Alert Type | Approval |
Drug Name | Apitegromab-mstn |
Brand Name | Isembyld |
Company | Scholar Rock |
Regulatory Authority | U.S. Food and Drug Administration |
Approval Type | New drug approval |
Indication | Treatment of spinal muscular atrophy in adults and paediatric patients aged 2 years and older receiving an SMN2-targeted therapy |
Therapy Area(s) | Neurology; rare disease; neuromuscular disease |
Technology or Modality | Monoclonal antibody; myostatin inhibitor |
Geography | United States |
What Happened | The FDA approved Isembyld (apitegromab-mstn) for adults and children aged 2 years and older with spinal muscular atrophy who are receiving an SMN2-targeted treatment. |
Why It Matters | Isembyld is the first approved SMA treatment designed to directly target muscle loss, providing a complementary mechanism to existing therapies that act on the underlying SMN pathway. |
Supporting Context | Apitegromab-mstn is a monoclonal antibody designed to selectively inhibit activation of myostatin, a negative regulator of skeletal muscle growth. |
Key Takeaway | Isembyld introduces the first FDA-approved muscle-targeted treatment for eligible patients with spinal muscular atrophy. |
What to Watch | Clinical uptake alongside SMN2-targeted therapies and longer-term evidence on motor function and treatment outcomes across SMA populations. |
Primary Source | U.S. Food and Drug Administration |
Relevant Date | 11 September 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
コメント